Skip to content
Screener

PTC Therapeutics PTCT Return on equity

Discontinued — last reported Q4 '21

Return on equity at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-9.3%+2,662pp
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
9.1%+2.8pp
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
-56.4%-11.3pp
ALN
Alnylam PharmaceuticalsALNY
91.4%—
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
-38.1%+13.4pp
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
-58.9%-4.4pp

Other financials

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total debt$395.1M+0.1%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation

See full
Market cap$5.78B+41.9%
Enterprise value$5.34B+54.9%
P/E7.1×—
P/S7×+4.7×

Profitability

See full
Gross margin96%—
Operating margin1.6%-38.7pp
Net margin42.3%+27.4pp
FCF margin39.1%+32.8pp

Returns & leverage

See full
Debt / equity372.3×—
Current ratio2.4×-1.5×

Where this comes from

Calculated from PTC Therapeutics’s reported figures.

net income/total stockholders equity=-216.7%

Based on trailing twelve months.

The source filing: PTC Therapeutics’s 10-K, filed February 21, 2023. Open the filing →

Filed
Feb 21, 2023
Fiscal year
FY2022
Accession
0001070081-23-000011

FAQ

What is PTC Therapeutics's return on equity?
PTC Therapeutics (PTCT) reported return on equity of -216.7% in Q4 2021.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

Ask your AI about PTC Therapeutics's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude